Market intelligence
All coverage
BitMine Immersion Technologies dropped 7.14% on Friday, wiping out approximately $1.10 billion in market capitalisation. The fall outpaced Ether's decline of about 3%.
BMNR selloff versus marked Ethereum assets
ETH marked at $2,438; other assets use August 23 company disclosures. Market cap uses 603.23M shares and Friday's close.
| ETH held | 5.848M |
| ETH staked | 5.067M |
| Share staked | 86.7% |
| 7-day yield | 2.67% |
| Annualized revenue | $330M |
| Measure | Current | Change / sensitivity |
|---|---|---|
| BMNR | $23.80 | −7.14% |
| Ether | ≈$2,438 | ≈−3.0% / 24h |
| Value impact of 1% ETH move | — | ≈$143M |
| Quarterly common-holder loss | May 2026 | −$83.6M |
| Stockholders' equity | May 2026 | $11.60B |
U.S. interest in “apple watch ultra 4” increased following Apple’s announcement of a product event set for September 9, drawing renewed focus to a…
| Item | Status | Investor use |
|---|---|---|
| Apple event | Confirmed | Launch catalyst |
| “Apple Watch Ultra 4” | Not announced | Search term only |
| Current Ultra 3 | $799; 42 hours | Price and battery benchmark |
| Ultra revenue | Not disclosed | Tracked inside $7.88B category |
| Upside | Premium price holds and new health or connectivity features widen upgrade demand. |
| Middle | Incremental update sustains category growth near the latest 6.5% rate. |
| Downside | Limited differentiation shifts buyers to cheaper Watch models or delays upgrades. |
NEW YORK, August 28, 2026, 19:25. Keel Infrastructure shares were down 8% after the company disclosed $819 million in liquidity and confirmed its 2.2-gigawatt…
| Metric | Q2 2026 | Change |
|---|---|---|
| Revenue | $30.4M | -50% |
| Operating result | -$141M | From +$11M |
| Adjusted EBITDA | -$23.7M | From +$6.6M |
| Continuing loss | -$64M | -$0.11/share |
| Milestone | Current state | Signal |
|---|---|---|
| Commercial demand | Negotiations at three sites | Signed lease needed |
| Washington HPC | 18 MW conversion | No HPC revenue yet |
| Funding | $458M convertibles | 1.25%, due 2032 |
| Legacy exit | Mining decommissioned at key sites | Near-term revenue gap |
The valuation case depends on converting powered land into long-duration AI leases before liquidity is consumed. Each 100 MW of signed capacity would materially improve visibility, but economics remain undisclosed.
Weekly Recap + Week Ahead: Tech Rebounds Before GDP29/08/2026 · 08:36 AEST WEEKLY RECAP + WEEK AHEAD Tech rescued Friday; rates still set the…
Bayern Munich opened Germany's 2026-27 Bundesliga season with a 5-1 home win over VfB Stuttgart. The result converted a prominent U.S. search trend into…
| Stage | Event | Read-through |
|---|---|---|
| 1–0 | Dayot Upamecano | Early control |
| 1–1 | Josha Vagnoman | Brief reset |
| 2–1 | Michael Olise | Lead restored |
| 3–1 | Own goal | Pressure compounds |
| 4–1 / 5–1 | Pavlović / Díaz | Late separation |
| Standalone window | 20:30 CEST season opener |
| Title narrative | 5–1 opening statement |
| Recognizable names | Olise, Díaz, Neuer |
| Milestone | Neuer’s 600th Bayern appearance |
| Away support | About 7,500 Stuttgart fans |
| Signal | Verified evidence | Commercial meaning |
|---|---|---|
| Sporting strength | 5 goals; 21 shots; 58.9% possession | Supports premium broadcast positioning |
| Scarcity | Every home league match oversubscribed 2×+ | Pricing and hospitality leverage |
| U.S. search interest | Trend surfaced around opening-night result | Audience signal, not a direct equity trade |
| Ownership | Both clubs remain member-controlled | No clean listed-stock exposure |
One result cannot establish season-long television audiences, merchandise sales or sponsor returns. Search interest can fade quickly, and club economics remain less transparent than listed-company reporting.
U.S. equity benchmarks held near their closing levels through 18:00 EDT. Thin after-hours trading did not extend Friday’s technology-led selloff.
| Communication services | +1.41% |
| Energy | +0.60% |
| Utilities | −1.08% |
| Technology | −1.55% |
| Gap | ≈+13% |
| Workday | +5.8% |
| Nvidia | −4.6% |
| Marvell | −10.3% |
| PayPal | −12.7% |
Sources: AP, Reuters, WSJ market data and StockAnalysis after-hours snapshot. Figures timestamped Aug. 28, 2026, 18:00 EDT unless noted.
SANTA CLARA, August 28, 2026, 18:00. Intel's stock declined 2.8%, trading under its $95 offering level, as the company's $20 billion investment in its…
| Company | Close move | Market signal |
|---|---|---|
| Marvell | −10.39% | Google-deal economics |
| Nvidia | −4.59% | Margin reset |
| Intel | −2.83% | Funding/foundry test |
| AMD | −2.34% | Sector repricing |
| Consensus | Hold |
| Ratings | 5 Buy · 24 Hold · 2 Sell |
| Average target | $116.84 |
| Implied upside | +30.6% |
| Target range | $80–$200 |
Sources: market data at Aug. 28 close; Intel Newsroom; Reuters; analyst consensus updated Aug. 28, 2026.
BELGRADE, Montana, August 28, 2026, 14:45. Xtant Medical stock advanced 16% after BioHorizons agreed to introduce the Prolifica line to its dental sales channel,…
BioHorizons opens a new channel. Contract economics remain private.
Xtant: developer, processor and manufacturer. BioHorizons: exclusive U.S./Canada dental and oral-maxillofacial distributor. Brand: Prolifica. Status: available now.
Price, royalties, minimum orders and initial stocking volumes were not disclosed.
| Metric | Q2 2026 | YoY |
|---|---|---|
| Revenue | $23.0m | −35% |
| Gross margin | 57.9% | −10.7 pts |
| Net result | −$9.4m | vs +$3.6m |
| Adjusted EBITDA | −$2.7m | vs +$6.9m |
| Company | Price | Day | Market value | Read-through |
|---|---|---|---|---|
| Xtant (XTNT) | $0.384 | +16.36% | $53.9m | Direct product upside |
| Henry Schein (HSIC) | $89.52 | −0.85% | $10.24bn | BioHorizons parent |
| Orthofix (OFIX) | $9.70 | +0.73% | $396.8m | Orthobiologics peer |
| Globus Medical (GMED) | $82.97 | +0.52% | $11.40bn | Device peer |
Initial purchase orders; recognized Prolifica revenue; repeat clinician orders; disclosed gross-margin contribution; evidence that dental demand offsets weaker core biologics sales.
Economics: private terms. Adoption: no volume forecast. Liquidity: debt exceeds cash. Trading: micro-cap volatility and exceptional turnover.
The BioHorizons partnership can extend Xtant into a new clinical market without duplicating a dental sales network. The $7.6 million equity-value gain is smaller than one quarter of revenue but large beside available liquidity. Investors now need orders and margin data to convert channel access into a cash-flow case.
Sources: Xtant partnership announcement; Xtant Q2 results; StockAnalysis; Google Finance. Historical data and management guidance, not investment advice.
Cyabra, Inc. shares surged 48.6% on Friday following news that the narrative-intelligence firm secured a six-figure yearly gaming agreement.
The contract can be material to revenue, but the undisclosed value leaves a tenfold range. The market-value gain of about $2.06 million equals 2.1×–20.6× that annual range.
Open $0.37 · Prior close $0.3073. The 93.5% low-to-high span shows unusually unstable price discovery.
| Metric | Q2 2025 | Q2 2026 | Change |
|---|---|---|---|
| Revenue | $1.3m | $1.9m | +39% |
| Gross profit | $1.1m | $1.5m | +39% |
| Gross margin | ≈84% | ≈84% | Flat |
| Operating loss | $3.4m | $3.1m | Improved |
| Net loss | $2.4m | $3.4m | Wider |
| Cash at June 30 | $0.794m |
| H1 operating cash use | $4.995m |
| Q2 operating cash use | $2.397m |
| Private placement | $6.0m |
| Accumulated deficit | $61.6m |
| Going-concern disclosure | Present |
Management said existing liquidity was insufficient for at least one year. Contract wins must be weighed against continuing financing needs.
Commercial proof versus cash burn: The unnamed publisher validates private-sector demand. Yet Q2 operating loss was 1.6 times revenue, and first-half operating cash use exceeded June cash by more than sixfold.
Friday volume equaled about 41 times the reported 5.02 million-share public float.
Volume also exceeded total shares outstanding by roughly 13 times. A reversal can be as violent as the initial move.
NEW YORK, August 28, 2026, 13:37 EDT – Exascale Labs opened on the Nasdaq with its shares rising 12%, as the company debuted with…
Exascale Labs drew heavy trading on its first Nasdaq session. The valuation case now rests on converting a large reported pipeline while funding an asset-heavy GPU capacity strategy.
| Quarter | Revenue |
|---|---|
| Q4 2023 | $0.068m |
| Q1 2024 | $0.479m |
| Q2 2024 | $0.770m |
| Q3 2024 | $1.171m |
| Q4 2024 | $1.442m |
| Q1 2025 | $2.160m |
| Q2 2025 | $2.242m |
| Q3 2025 | $3.262m |
| Q4 2025 | $3.545m |
The company reported 64% average quarterly growth across this sequence. FY2025 revenue totaled $7.0 million.
A three-year agreement committed about $71.4 million to dedicated GPU capacity. It is a procurement obligation, not customer revenue.
Shareholders approved the combination. Roughly $12 million remained in trust after redemptions, before transaction expenses.
The business combination closed. Management cited a qualified pipeline exceeding $300 million.
XLAB shares and XLABW warrants began Nasdaq trading.
Sources: MarketWatch market data; closing announcement; SEC filing on trust cash; SEC investor presentation; GPU capacity agreement. Financial figures reflect company disclosures and are not forecasts.
Weekly Recap + Week Ahead: AI Splits Asia Before China PMI29/08/2026 · 08:51 SGT WEEKLY RECAP + WEEK AHEAD AI leadership held, but rate…
NEW YORK, August 28, 2026, 11:13 – SharonAI shares slid 4.2% as uncertainty grew over its $4.88 billion deal with Nvidia, following Nvidia's decision…
Reuters reported Nvidia paused some credit-support deals that exchanged financing help for cloud-revenue participation.
Nvidia said the broader compute-access model remains in place and continues to evolve.
| Metric | Value | Signal |
|---|---|---|
| Revenue | $1.93M | +412% YoY |
| Adjusted EBITDA | $0.59M | Positive |
| Net loss | −$430.4M | Mostly non-cash |
| Cash | $1.861B | Build-out buffer |
| Current note liabilities | $1.007B | Financing weight |
| Checkpoint | Why it matters |
|---|---|
| Financing terms | Determines deployment cost and equity dilution |
| GPU acceptance | Triggers capacity availability and revenue |
| Customer utilization | Turns reserved capacity into billed sales |
| Contract amendments | Tests whether Nvidia's pause reaches SharonAI |
| Cash burn | Measures runway during infrastructure ramp |
The stock move values implementation risk, not simply demand. SharonAI's SEC filing already says deployments need additional debt or equity financing and face phased acceptance tests.
Key question: can $8.8 billion of contracted value convert into revenue without costly new capital?
CAMBRIDGE, Massachusetts, August 28, 2026, 09:47 - Moderna shares declined by 3.4% as the company launched a $2.6 billion convertible bond offering, putting its…
Reference points: $137.25 open, $147.77 high, $134.07 low, $137.86 latest.
Initial conversion equals roughly 3.1% of the June share base. The capped call is designed to offset dilution, but only up to its cap.
2032 maturityRule 144ASenior unsecured| Measure | Term | What it changes |
|---|---|---|
| Initial conversion | $210.58 | 47.5% premium to Thursday close |
| Capped-call ceiling | $392.6175 | Hedge protection to 175% premium |
| Expected net proceeds | $2.563bn | About 37% of June liquidity |
| Capped-call cost | $285m | About 11% of base net proceeds |
| Buyer option | Up to $400m | Could lift net proceeds near $2.96bn |
The financing replenishes flexibility after the settlement payment and ongoing research spending.
| Q2 revenue | $145m |
| Q2 EPS | −$1.97 |
| 2026 revenue plan | Up to +10% |
| Year-end cash guide | $4.7–$5.2bn |
| Analyst consensus | Hold |
| Average target | $106.63 |
Bull case: zero-coupon funding protects oncology momentum and the hedge limits dilution. Bear case: the stock remains above consensus value while cash burn and vaccine demand stay uncertain.
Ulta Beauty stock fell on Friday, even after the company surpassed quarterly expectations and raised its full-year outlook. The 1.5% drop before the market…
The quarter beat consensus, but comparable growth slowed from 6.7% a year earlier and gross margin eased 10 basis points.
The one-month gain was 5.32% through Aug. 27, leaving less room for a merely good print.
| Fiscal 2026 | Prior | Updated |
|---|---|---|
| Net sales growth | 6.0%–7.0% | 6.7%–7.2% |
| Comparable sales | 2.5%–3.5% | 3.2%–3.7% |
| Operating income growth | 6.5%–9.0% | 8.3%–9.3% |
| Diluted EPS | $28.36–$28.80 | $28.70–$29.00 |
| Fiscal-year repurchases | $1.5B | $1.8B |
Bars share a $2.4 billion scale. Repurchases can support per-share earnings, but debt exceeds cash plus short-term investments.
| Signal | Current read | What changes the view |
|---|---|---|
| Demand | 3.8% comps; no reported trade-down | Holiday traffic and prestige mix |
| Margin | 39.1% gross; 12.5% operating | Space NK mix and markdowns |
| Inventory | $2.4B, roughly flat YoY | Sell-through versus new launches |
| Capital returns | $1.8B fiscal-year plan | Execution against $1.0B authorization remaining |
| Valuation | 20.24× trailing EPS | Evidence that raised guidance is conservative |
Ulta Beauty results
Reuters earnings report
MarketWatch quote
Google Finance listing
All figures are company-reported or cited to the timestamped market sources above. Rounded totals may not sum exactly.
SANTA CLARA, California, August 28, 2026, 07:21 — Marvell Technology fell 6.9% as investors reacted to Google's adjusted forecast, placing significant AI-related revenue gains…
Management lifted fiscal 2027 guidance by about $500 million and fiscal 2028 guidance by about $1.5 billion.
| Metric | Q2 FY27 | Signal |
|---|---|---|
| Revenue | $2.739B | +37% |
| Adjusted EPS | $0.94 | $0.93 est. |
| GAAP net income | $308M | +58% |
| Operating cash flow | $605.5M | 22.1% margin |
| Non-GAAP gross margin | 58.9% | Profitable scale |
| Signal | Current view | Investor meaning |
|---|---|---|
| Q3 revenue | $3.15B ±5% | More than 50% growth implied |
| Q3 adjusted EPS | $1.10 ±$0.05 | Above Q2 run-rate |
| Google contribution | Some through FY28 | Larger in FY29 |
| Investor Day | Oct. 6, 2026 | Next major detail point |
The median target offers roughly 22% upside from premarket. Forward P/E is 58.4×, versus 32.2× for Broadcom.
Rubrik, Inc. stock dropped 6.7% in premarket trade on Friday, even after the company surpassed quarterly expectations. The slide wiped about $1.5 billion in…
The selloff reversed part of Thursday’s 11.3% surge. Premarket price remained 3.9% above Wednesday’s close, supporting an expectations-reset reading.
| Metric | Q2 FY27 | Signal |
|---|---|---|
| Revenue | $427.3M | +38% |
| Subscription revenue | $407.2M | +37% |
| Cloud ARR | $1.48B | +39% |
| $100K+ ARR customers | 3,084 | +23% |
| Free cash flow | $65.7M | 15% margin |
| Fiscal 2027 | New range | Prior range |
|---|---|---|
| Revenue | $1.685B–$1.693B | $1.638B–$1.648B |
| Adjusted EPS | $0.47–$0.53 | $0.25–$0.35 |
| Subscription ARR | $1.880B–$1.885B | Raised |
| Free cash flow | $323M–$333M | Raised |
Twenty-eight analysts tracked by StockAnalysis rate the shares Buy or Strong Buy. New post-results targets included $115, $120 and $130.
![Australia Stock Market Today 29/08/2026 [UPDATE: 08:36 AEST] [Weekly Recap + Week Ahead: Tech Rebounds Before GDP]](https://ts2.tech/wp-content/uploads/2026/08/AU-market-dashboard-2026-08-29-0830-1024x683.jpg "Australia Stock Market Today 29/08/2026 [UPDATE: 08:36 AEST] [Weekly Recap + Week Ahead: Tech Rebounds Before GDP]")
![Asia Stock Market Today 29/08/2026 [UPDATE: 08:51 SGT] [Weekly Recap + Week Ahead: AI Splits Asia Before China PMI]](https://ts2.tech/wp-content/uploads/2026/08/Asia-market-dashboard-2026-08-29-0851-1024x683.jpg "Asia Stock Market Today 29/08/2026 [UPDATE: 08:51 SGT] [Weekly Recap + Week Ahead: AI Splits Asia Before China PMI]")
